A

Alabama Oncology | Research department

Research site
(Unclaimed)
Location
500 Office Park Drive , suite 400, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Sacituzumab
Debio 1562
TAK-079
Pembrolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 4 total trials

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in comb...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Lenalidomide

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Trial sponsors

Debiopharm logo
F
Gilead Sciences logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems